Qu Biologics secures $4 mln more for immunotherapy research
Vancouver-based biotechnology company Qu Biologics Inc recently secured $4 million in private equity financing, bringing its total funding to $23 million. The investors were not disclosed. Founded in 2007 by Dr. Hal Gunn and businessman Rob Freeman, Qu Biologics specializes in the development of site-specific immunomodulators that aim to restore the body’s normal immune response to chronic disease. Funds raised will be used to expand the company's clinical and non-clinical programs this year.
21 April 2016•3 mins read
